Viking Therapeutics

Viking Therapeutics Advances Weight-Loss Drug to Final Clinical Stage

angelina - March 13, 2026

Viking Therapeutics: A High-Stakes Bet on a Single Drug Candidate

March 9, 2026

Viking Therapeutics: Key Clinical Catalysts and Investor Activity

kashif hafeez - March 4, 2026

Viking Therapeutics: A Strategic Pivot Fueled by Cash and Clinical Catalysts

kashif hafeez - March 3, 2026

Viking Therapeutics Charts Course for Late-Stage Obesity Drug Trials

kashif hafeez - February 11, 2026

Viking Therapeutics: Investors Await Crucial Pipeline Updates

angelina - February 9, 2026

Investor Focus Intensifies Ahead of Viking Therapeutics Update

February 9, 2026

Viking Therapeutics Advances Key Obesity Drug Program

Brett Shapiro - February 3, 2026

Viking Therapeutics Stock: Analyst Forecasts 170% Upside Potential

kashif hafeez - December 27, 2025

Viking Therapeutics Emerges as Prime Acquisition Candidate in Obesity Drug Race

kashif hafeez - December 16, 2025

Institutional Investors Pile Into Viking Therapeutics Stock

angelina - December 13, 2025

Viking Therapeutics Gains Momentum as Key Clinical and Financial Catalysts Align

angelina - December 12, 2025

Institutional Investors Signal Confidence in Viking Therapeutics’ Weight-Loss Ambitions

angelina - December 12, 2025

Viking Therapeutics Stock Finds Its Footing After Recent Swings

Brett Shapiro - December 11, 2025

Major Investor Boosts Stake in Viking Therapeutics Amid Insider Sales

Brett Shapiro - December 6, 2025

12 3 Page 1 of 3